NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MAXALT-MLT (rizatriptan benzoate) by Merck & Co. is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache (), migraine. First approved in 1998.
Drug data last refreshed 1w ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXALT-MLT (rizatriptan benzoate) is an oral, orally disintegrating tablet approved in 1998 for acute treatment of migraine attacks and cluster headaches. It works by binding to 5-HT 1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting neuropeptide release.
LOE Approaching
MAXALT-MLT faces significant competitive pressure (30/100 intensity) as a near-LOE branded small molecule, likely requiring defensive marketing and smaller team operations.
Mechanism of Action
5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Indications (3)
Worked on MAXALT-MLT at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.